Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Prepaid Assets: 2020-2025

Historic Prepaid Assets for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $1.8 million.

  • SAB Biotherapeutics' Prepaid Assets fell 9.96% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 9.96%. This contributed to the annual value of $3.0 million for FY2024, which is 27.16% up from last year.
  • SAB Biotherapeutics' Prepaid Assets amounted to $1.8 million in Q3 2025, which was down 48.92% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Prepaid Assets registered a high of $3.6 million during Q2 2025, and its lowest value of $102,742 during Q3 2021.
  • Moreover, its 3-year median value for Prepaid Assets was $2.0 million (2024), whereas its average is $2.2 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Prepaid Assets spiked by 1,038.56% in 2022 and then plummeted by 59.57% in 2023.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Prepaid Assets stood at $2.6 million in 2021, then slumped by 43.33% to $1.5 million in 2022, then spiked by 56.68% to $2.3 million in 2023, then climbed by 27.16% to $3.0 million in 2024, then declined by 9.96% to $1.8 million in 2025.
  • Its Prepaid Assets stands at $1.8 million for Q3 2025, versus $3.6 million for Q2 2025 and $3.4 million for Q1 2025.